Abiopharma

🔍 Kooij Louise Frederika (Executive)

Company: NewAmsterdam Pharma Co N.V. (NAMS)

Report Date: 2026-01-23

Detailed Transactions and Holdings:

• Acquired 38,172 shares of Ordinary Shares at $10.9 per share (Direct)
  Date: 2026-01-23 | Code: M | equity_swap_involved: false | shares_owned_after: 62,525.00 | transaction_form_type: 4
• Sold 25,405 shares of Ordinary Shares at $33.44 per share (Direct)
  Date: 2026-01-23 | Code: S | equity_swap_involved: false | shares_owned_after: 37,120.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,767 shares of Ordinary Shares at $34.37 per share (Direct)
  Date: 2026-01-23 | Code: S | equity_swap_involved: false | shares_owned_after: 24,353.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 34,400 shares of Ordinary Shares at $10.9 per share (Direct)
  Date: 2026-01-26 | Code: M | equity_swap_involved: false | shares_owned_after: 58,753.00 | transaction_form_type: 4
• Sold 34,091 shares of Ordinary Shares at $32.77 per share (Direct)
  Date: 2026-01-26 | Code: S | equity_swap_involved: false | shares_owned_after: 24,662.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 309 shares of Ordinary Shares at $33.45 per share (Direct)
  Date: 2026-01-26 | Code: S | equity_swap_involved: false | shares_owned_after: 24,353.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 38,172 shares of Option (right to buy) at $10.9 per share (Derivative)
  Date: 2026-01-23 | Code: M | Expires: 2033-01-01 | equity_swap_involved: false | shares_owned_after: 179,962.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 34,400 shares of Option (right to buy) at $10.9 per share (Derivative)
  Date: 2026-01-26 | Code: M | Expires: 2033-01-01 | equity_swap_involved: false | shares_owned_after: 145,562.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $34.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.40 to $33.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.40 to $33.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.